Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Heart Failure Clinical Trial

— Canacardia  

Official title:

Subclinical Inflammation, Myocardial Function and Fatty Acid Metabolism in Patients With Type 2 Diabetes and Heart Failure: Impact of a Short-term Treatment With Canagliflozin - a Pilot Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03298009
• Other study ID #: 28431754DIA4029
• Status: Withdrawn
• Phase: N/A
• Start date: November 1, 2017
• Est. completion date: January 1, 2019

Study information

• Verified date: April 2019
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency.

Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between.

At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.

Description:

Non-invasive Positron Emission Tomography (PET) imaging method allows to measure myocardial uptake and organ-specific partitioning of dietary fatty acids (DFA). It allows to study kidney, liver, skeletal muscles and adipose tissues DFA utilization, whole body fatty acid turnover and oxidation rates, myocardial oxidative metabolism and left ventricular (LV) function that are other likely targets of SGLT-2 inhibitors. Thus, the PET is ideal to verify the very interesting hypothesis that, increase in liver fatty acid utilization and/or adipose tissue dietary fatty acid uptake, may lead to reduced cardiac utilization of fatty acids and improved cardiac energetic efficiency.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2019
• Est. primary completion date: November 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• HbA1c 7.5 -10.5%;

• LVEF < 40%;

• NYHA class 2 or 3;

• NT pro-BNP level > 600 pg/mL;

• Being on a stable-dose metformin therapy max 2500 mg/day or other hypoglycemic therapy and RAAS-blocking agents for at least 8 weeks;

• Being on optimal and stable-doses of heart failure medication including diuretics for at least 4 weeks;

Exclusion Criteria:

• age <18 yo;

• NYHA class 4;

• Treatment with a fibrate or thiazolidinedione;

• Unstable or advanced renal failure;

• Unstable or new medical or surgical condition within the past 3 months;

• Heart failure caused by active inflammatory condition such as sarcoidosis or any form of myocarditis;

• History of diabetic ketoacidosis;

• Not on a stable regimen for at least 8 weeks before the screening visit;

• Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment;

• Patients post bariatric surgery, or on weight loss medication;

• Contraindications to metformin, including allergy or intolerance;

• Hospitalization for heart failure within the 60 days prior to enrollment;

• Admission for an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within the 60 days prior to enrollment;

• Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment;

• Patients who are volume depleted based upon physical examination at the time of enrollment;

• Chronic disabling illness;

• History of substance abuse.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Heart Failure
• Type2 Diabetes

Intervention

Drug:
• Canagliflozin 100mg
2-week intervention
• Placebo oral capsule
2-week intervention

Radiation:
• PET imaging
1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Université de Sherbrooke	Janssen Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Insulin sensitivity	will be determined using the HOMA-IR (based on fasting insulin and glucose levels)	1 year
Other	Insulin secretion rate	will be assessed using deconvolution of plasma C-peptide with standard Cpeptide kinetic parameters	1 year
Other	ß-cell function	will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin	1 year
Other	hormonal response	will be determined using a multiplex assay system	1 year
Other	Biomarkers	Assays will be performed using the BIOPLEX	1 year
Other	body composition	DXA	3 months
Primary	Change to be observed with canagliflozin on myocardial dietary fatty acid uptake	will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid ([18F]-FTHA) with sequential dynamic.; PET/CT scanning.	3 months
Primary	Change to be observed with canagliflozin on whole-body partitioning.	will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid ([18F]-FTHA, with static PET/CT scanning	3 months
Secondary	myocardial and liver NEFA uptake	using PET with [11C]-palmitate	3 months
Secondary	NEFA oxidative rate	using PET with [11C]-acetate	3 months
Secondary	plasma NEFA turnover	using i.v. infusion of [U-13C]-palmitate	1 year